Medicus Pharma sees catalyst-rich year ahead as SkinJect and Teverelix progress

Medicus Pharma (NASDAQ:MDCX) reported first quarter 2026 financial results on Thursday, highlighting progress across its SkinJect and Teverelix clinical...